CTKB

Cytek Biosciences, Inc. Common Stock

4.58

USD

CTKB Earnings Reports

Positive Surprise Ratio

CTKB beat 10 of 19 last estimates.

53%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$44.83M

-$0.07

Implied change from Q4 25 (Revenue/ EPS)

-27.86%

+75.00%

Implied change from Q1 25 (Revenue/ EPS)

+8.13%

-22.22%

Cytek Biosciences, Inc. Common Stock earnings per share and revenue

On Feb 26, 2026, CTKB reported earnings of -0.04 USD per share (EPS) for Q4 25, missing the estimate of -0.02 USD, resulting in a -96.08% surprise. Revenue reached 62.14 million, compared to an expected 58.33 million, with a 6.53% difference. The market reacted with a -3.91% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 44.83 million USD, implying an increase of 75.00% EPS, and decrease of -27.86% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Cytek Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Cytek Biosciences, Inc. Common Stock reported EPS of -$0.04, missing estimates by -96.08%, and revenue of $62.14M, 6.53% above expectations.

How did the market react to Cytek Biosciences, Inc. Common Stock's Q4 2025 earnings?

The stock price moved down -3.91%, changed from $5.62 before the earnings release to $5.40 the day after.

When is Cytek Biosciences, Inc. Common Stock expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for Cytek Biosciences, Inc. Common Stock's next earnings report?

Based on 7 analysts, Cytek Biosciences, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $44.83M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.